Connect with us

Health

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis – GlobeNewswire

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and…

Published

on

ADVERTISEMENT

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that on the recommendation of the European Medicines Agency (EMA), the European Commission has granted orphan medicinal product designation for OCU400 (AAV5-hNR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Single Shot Of Coronavirus Vaccine After Illness Could Extend Supply : Shots – Health News – NPR
Article feature image
A Covid Vaccine Side Effect, Enlarged Lymph Nodes, Can Be Mistaken for Cancer – The New York Times
Article feature image
Michigan coronavirus cases up to 589,150; Death toll now at 15,534 – WDIV ClickOnDetroit